Clinical Trial

A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)

Dimensions: NCT02003144

Investigators

Affiliations

Organisations

Sponsors/collaborators

Abstract

The purpose of this study is to determine whether eculizumab long-term use is safe and effective in patients with relapsing NMO. Detailed Description This study is an open label extension study to confirm the long term safety and efficacy of eculizumab in subjects with relapsing NMO who have completed the initial double-blind, randomized, placebo-controlled trial ECU-NMO-301.

Methods

Condition: Neuromyelitis Optica

Recruitment information

Gender: All

Trial period

2015-2021

Phase

Phase 3

Research Categories

Main Subject Area

Fields of Research

External sources

Access at Registry